Creative Planning’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Creative Planning’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,429	Closed	-$13K	–	2297
2020 Q2	$13K	Hold	1,429	–	–	﹤0.01%	1863
2020 Q1	$21K	Buy	+1,429	New	+$31K	﹤0.01%	1720
2017 Q4	–	Sell	-571	Closed	-$39K	–	2018
2017 Q3	$39K	Buy	571 +142	+33%	+$11.6K	﹤0.01%	1800
2017 Q2	$41K	Buy	+429	New	+$49.2K	﹤0.01%	2671
2017 Q1	–	Sell	-143	Closed	-$18K	–	4951
2016 Q4	$18K	Buy	+143	New	+$19.9K	﹤0.01%	3152
2015 Q2	–	Sell	-2	Closed	-$1K	–	3127
2015 Q1	$1K	Hold	2	–	–	﹤0.01%	4091
2014 Q4	$1K	Sell	2 -1	-33%	-$451	﹤0.01%	4020
2014 Q3	$5K	Buy	3 +1	+50%	+$1.45K	﹤0.01%	3321
2014 Q2	$3K	Buy	+2	New	+$2.32K	﹤0.01%	3431

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Creative Planning's VIRX Position: Q3 2020 in Review

Creative Planning sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2020, closing a stake of 1,429 shares — an estimated $13K sold.

Creative Planning first reported a position in VIRX in Q2 2014 and held it in 9 quarters. The position peaked at $41K in Q2 2017. 28 funds tracked by Wall St. Rank hold VIRX as of Q3 2020.

Creative Planning reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Creative Planning sold 1,429 Viracta Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $13K.
Creative Planning first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 9 quarters.
Creative Planning's Viracta Therapeutics, Inc. Common Stock position peaked at $41K in Q2 2017.
28 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Creative Planning's 13F filing for Q3 2020, filed 5 Nov 2020.